We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Landos Biopharma Inc (LABP) USD0.01

Sell:$6.58 Buy:$6.60 Change: $0.06 (0.92%)
Market closed |  Prices as at close on 8 December 2021 | Switch to live prices |
Change: $0.06 (0.92%)
Market closed |  Prices as at close on 8 December 2021 | Switch to live prices |
Change: $0.06 (0.92%)
Market closed |  Prices as at close on 8 December 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Landos Biopharma, Inc. is a clinical-stage biotechnology company. The Company is engaged in focused on the discovery and development of oral therapeutics for patients with autoimmune diseases. The Company through its artificial intelligence (AI)-based precision medicine platform, LANCE platform, identifies novel therapeutic targets based on predictions of immunometabolic function and create therapeutic candidates to engage those targets in areas of unmet medical need. It identifies novel immunometabolic targets and product candidates to date across indications such as ulcerative colitis (UC), Crohn’s disease (CD), lupus, rheumatoid arthritis, nonalcoholic steatohepatitis (NASH), multiple sclerosis, Alzheimer’s disease, asthma, psoriasis, atopic dermatitis, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), diabetic nephropathy and type 1 diabetes. Its clinical asset, BT-11, is a locally acting small molecule targeting inflammatory bowel disease (IBD).

Contact details

1800 Kraft Drive, Suite 216
United States
+1 (540) 8182844

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$251.47 million
Shares in issue:
40.24 million
United States
US dollar

Key personnel

  • Christopher Garabedian
    Chairman of the Board
  • Timothy Mayleben
    Interim President, Chief Executive Officer, Director
  • Patricia Bitar
    Interim Chief Financial Officer
  • Raquel Hontecillas
    Chief Scientific Officer
  • Jyoti Chauhan
    Executive Director of Global Clinical Operations and Regulatory Affairs

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.